Michael Linden, M.D., Ph.D.

Professor, Department of Laboratory Medicine and Pathology

Michael Linden

Contact Info


Office Phone Clinic 612-273-5136

Lab Phone 612-273-5136

Mailing Address:
MMC 609 Mayo
420 Delaware St SE
Minneapolis, MN 55455

MD, MD, PhD University of Minnesota (Medical Scientist Training Program), 2006

University of Washington, Seattle (Anatomic and Clinical Pathology), 2006-2010

University of Washington, Seattle (Hematopathology), 2010-2011

Saint Mary's University, Winona, MN (Biology), 1998


Awards & Recognition

  • Rising Star, Mpls. St. Paul Magazine, 2021
  • Rising Star, Mpls. St. Paul Magazine, 2020
  • Rising Star, Mpls. St. Paul Magazine, 2019
  • Resident Distinguished Teaching Award in Clinical Pathology, 2018
  • Resident Distinguished Teaching Award in Clinical Pathology, 2012
  • Certificate of Excellence (top 5% of all reviewers for Laboratory Investigation), 2011
  • J. Jacob Kaplan Research Award, 2006
  • J. Thomas Livermore Research Award, 2004
  • University of Minnesota Medical School Advanced Admissions Program Acceptance, 1996
  • CRC Press Freshman Chemistry Award, 1995

Professional Associations

  • Academy of Clinical Laboratory Physicians and Scientists (ACLPS)
  • American Society for Clinical Pathology (ASCP)
  • American Society of Hematology (ASH)
  • College of American Pathologists (CAP)
    • Chair, Diagnostic Immunology and Flow Cytometry Committee, 2018-Present
  • Society for Hematopathology and European Association for Hematopathology (SH-EAHP)
  • United States and Canadian Academy of Pathology (USCAP)


Research Summary/Interests

Dr. Linden is Director of Hematopathology. As a graduate student, he developed a novel genetically engineered mouse model of multiple myeloma with characteristics similar to those found in human disease. Linden has continued doing research on multiple myeloma and other plasma cell neoplasms while translating that knowledge to clinical application through improved laboratory diagnoses, clinical monitoring, and prediction of disease resistance to therapy.

Multiple myeloma is characterized by the proliferation of malignant plasma cells within the bone marrow. Compared to other lymphoid malignancies, the disease has been difficult to study and treat due to its genetic heterogeneity. Investigators use murine and human myeloma cell lines, xenograft models, and genetically engineered mice to identify the multiple genetic pathways involved in the pathobiology of the disease as well as mechanisms of drug resistance. Linden is collaborating with colleagues who are using murine and human cell lines, in addition to primary human samples, to characterize genotypic and immunophenotypic signatures of drug resistance.

Linden’s laboratory is working to create new diagnostic tests that will aid in predicting chemotherapeutic sensitivity or disease resistance—an individualized therapy approach. In addition, as the analytic sensitivity of flow cytometric methods to evaluate for minimal residual disease is improving, Linden is working with the College of American Pathologists (CAP) to improve and standardize diagnostic testing.

In recent years the treatment approach to multiple myeloma has been the subject of a “cure versus control” discussion among clinicians. As novel chemotherapeutic combinations and transplant continue to improve treatment, the likelihood of cure continually increases. Simultaneously, clinical teams have asked for improved diagnostic testing to help define cure. Linden hopes to use his role as a CAP committee chair to guide efforts to improve standardization and quality of flow cytometric testing for myeloma patients.


Selected Invited or Peer-Reviewed Lectures

  • “Plasma cell neoplasms - a precision diagnostics approach for the practicing pathologist.” American Society for Clinical Pathology Annual Meeting, 2018
  • “Flow cytometry of blood and bone marrow: key diagnoses that you never want to miss.” College of American Pathologists Annual Meetings, 2015, 2016, 2017
  • “Plasma cell myeloma.” Carlos Alberto Escobedo Seguin Hospital and the Catholic University of Santa Maria Medical School, Arequipa, Peru, 2016.
  • “New CAP requirements to standardize flow cytometric MRD testing in myeloma.” Scientific Advisory Board, MRD in Myeloma, Bristol-Myers Squibb, Jersey City, NJ, 2016.
  • “New CAP requirements to improve MRD testing standardization.” Advances in MRD Testing in Myeloma Workshop, Multiple Myeloma Research Foundation, New York, NY, 2016.
  • “Practical flow cytometry to evaluate lymphoproliferative disorders of marrow” American Society for Clinical Pathology Annual Meeting, 2014 (presented in conjunction with Dr. Kristy Wolniak).
  • "Integrated laboratory diagnosis of plasma cell neoplasms – a morphologic, genetic, and flow cytometric approach." American Society of Clinical Pathology national meetings, Boston, MA and Chicago, IL - 2012, 2013
  • "Laboratory diagnosis of plasma cell dyscrasias and paraproteinemia associated disorders." Vanderbilt University Medical Center, Department of Pathology, Special Seminar, Nashville, TN - 2011
  • "Laboratory diagnosis of plasma cell dyscrasias and paraproteinemia associated disorders." University of California-Davis Department of Pathology and Laboratory Medicine Grand Rounds, Sacramento, CA – 2010

Selected Publications

For a more comprehensive list of publications, click HERE

  • Han SY, Mrózek K, Voutsinas J, Wu Q, Morgan EA, Vestergaard H, Ohgami R, Kluin PM, Kristensen TK, Pullarkat S, Møller MB, Schiefer AI, Baughn LB, Kim Y, Czuchlewski D, Hilberink JR, Horny HP, George TI, Dolan M, Ku NK, Arana Yi C, Pullarkat V, Kohlschmidt J, Salhotra A, Soma L, Bloomfield CD, Chen D, Sperr WR, Marcucci G, Cho C, Akin C, Gotlib J, Broesby-Olsen S, Larson M, Linden MA, Deeg HJ, Hoermann G, Perales MA, Hornick JL, Litzow MR, Nakamura R, Weisdorf D, Borthakur G, Huls G, Valent P, Ustun C, Yeung CCS. Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). Blood Adv. 2021 May 25;5(10):2481-2489. doi: 10.1182/bloodadvances.2020003605.


Board Certifications

American Board of Pathology

  • Anatomic and Clinical Pathology
  • Hematology

Clinical Interests

• Lymph node pathology • Bone marrow pathology • Flow cytometry • Minimal residual disease • External quality assurance/proficiency testing • Plasma cell myeloma